PitchSend

Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars KisqaliⓇ - CDK4/6 inhibitor NCT03701334 NATALEE (CLEE011012301C) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC) Phase 3 5101 Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions for Efficacy End Points in adjuvant breast cancer trials) Ribociclib endocrine therapy Endocrine therapy Pre and postmenopausal women and men with HR-positive, HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy Read-out Milestone(s) 2023 Publication TBD 52 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation